These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29077839)

  • 1. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.
    Srinivasan A; Vasudevan A; McFarlane A; Sparrow MP; Gibson PR; Van Langenberg DR
    J Crohns Colitis; 2018 Feb; 12(3):280-288. PubMed ID: 29077839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
    Pavlidis P; Gulati S; Dubois P; Chung-Faye G; Sherwood R; Bjarnason I; Hayee B
    Scand J Gastroenterol; 2016 Dec; 51(12):1447-1452. PubMed ID: 27400728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
    Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
    J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy.
    Noh SM; Oh EH; Park SH; Lee JB; Kim JY; Park JC; Kim J; Ham NS; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Ye BD
    J Crohns Colitis; 2020 Sep; 14(9):1231-1240. PubMed ID: 32157278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
    Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ
    J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
    Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
    Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
    [No Abstract]   [Full Text] [Related]  

  • 11. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
    Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
    Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
    Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
    J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
    Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
    Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses.
    Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg DR
    J Gastroenterol Hepatol; 2023 May; 38(5):724-732. PubMed ID: 36692034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A; Suzuki Y
    Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Srinivasan A; van Langenberg DR; Little RD; Sparrow MP; De Cruz P; Ward MG
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1342-1352. PubMed ID: 32379358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.